利用TCGA数据集分析E2F7在肺腺癌中的表达及临床意义

摘要
图/表
参考文献(17)
相关文章 (9)

全文: PDF (0 KB) HTML (28 KB)
输出: BibTeX | EndNote (RIS)

摘要目的研究转录因子E2F7 在肺腺癌及其癌旁组织中的表达及临床意义。方法从癌症基因组图谱（TCGA）数据库下载337 例肺腺癌组织（肿瘤组）与59 例癌旁组织（癌旁对照组）RNAseq 数据及对应的肺腺癌患者临床数据，对数据中E2F7 表达进行分析处理。分析比较E2F7 表达与肺腺癌临床病理特征的相关性及对预后的影响并通过COX 风险比例模型评估肺腺癌患者预后的独立危险因素。结果 E2F7 在肿瘤组中的表达水平高于癌旁对照组，差异有统计学意义（P＜0.05），T 分期、N 分期以及Stage 分期是E2F7 表达的相关因素（P＜0.05），生存分析显示肺腺癌中高表达E2F7 的患者预后差（P＜0.05），多因素COX 风险比例模型结果显示，高E2F7 表达水平、Stage 分期是肺腺癌患者预后差的独立危险因素（P＜0.05）。结论 E2F7 可能通过多种途径促进肺腺癌的发生、发展，进而影响肺腺癌患者的预后生存，因此，E2F7 可作为肺腺癌患者的预后标志物或潜在治疗靶点。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	赵秋荣
	郭静
	陈良远

关键词 ： E2F7, 肺腺癌, 癌症基因组图谱, 预后标志物

Abstract：Objective To investigate the expression and clinical significance of transcription factor E2F7 in lung adenocarcinoma and its adjacent tissues.Methods The RNAseq data of 337 cases of lung adenocarcinoma tissues(tumor group)and 59 cases of paracancer tissues(para-cancer control group)and the corresponding clinical data of lung adenocarcinoma patients were downloaded from the cancer genome atlas(TCGA)database,and the expression of E2F7 in the data set was analyzed and processed.The correlation between E2F7 expression and clinicopathological features of lung adenocarcinoma and its influence on the prognosis were analyzed and compared,and evaluate independent risk factors for the prognosis in patients with lung adenocarcinoma through the COX risk ratio model.Results The expression level of E2F7 in the tumor group was significantly higher than that in the para-carcinoma control group(P<0.05).T Stage,N Stage and Stage were relevant factors in E2F7 expression(P<0.05).Survival analysis showed that patients with high expression of E2F7 in lung adenocarcinoma had a poor prognosis(P<0.05).The results of the multivariate COX risk ratio model results showed that high E2F7 expression level and Stage were independent risk factors for poor prognosis in patients with lung adenocarcinoma(P<0.05).Conclusion E2F7 may promote the occurrence and development of lung adenocarcinoma through various ways,thus affecting the prognostic survival of patients with lung adenocarcinoma.Therefore,E2F7 can be used as a prognostic marker or potential therapeutic target for patients with lung adenocarcinoma.

Key words： E2F7 Lung adenocarcinoma Cancer genome map Prognostic marker

引用本文:

赵秋荣；郭静；陈良远. 利用TCGA数据集分析E2F7在肺腺癌中的表达及临床意义[J]. 中国当代医药, 2021, 28(27): 130-132.
ZHAO Qiu-rong；GUO Jing；CHEN Liang-yuan. Analysis of the expression and clinical significance of E2F7 expression in lung adenoarinoma utilizing TCGA datasets. 中国当代医药, 2021, 28(27): 130-132.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2021/V28/I27/130

[1]	Bray F，Ferlay J，Soerjomataram I，et al.Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin，2018，68（6）：394-424.
[2]	Siegel RL，Miller KD，Jemal A.Cancer statistics，2016[J].CA Cancer J Clin，2016，66（1）：7-30.
[3]	Chen WQ，Zheng RS，Baade PD，et al.Cancer statistics in China 2015[J].CA Cancer J Clin，2016，66（2）：115-132.
[4]	Sun CC，Li SJ，Hu W，et al.Comprehensive Analysis of the Expression and Prognosis for E2Fs in Human Breast Cancer[J].Mol Ther，2019，27（6）：1153-1165.
[5]	Attwooll C，Lazzerini DE，Helin K.The E2F family：specific functions and overlapping interests[J].EMBO J，2004，23（24）：4709-4716.
[6]	Chen HZ，Tsai SY，Leone G.Emerging roles of E2Fs in cancer：an exit from cell cycle control[J].Nat Rev Cancer，2009，9（11）：785-797.
[7]	Weijts BGMW，Westendorp B，Hien BT，et al.Atypical E2Fs inhibit tumor angiogenesis[J].Oncogene，2018，37（2）：271-276.
[8]	Emmrich S，Pützer BM.Checks and balances：E2F-microRNA crosstalk in cancer control[J].Cell Cycle，2010，9（13）：2555-2567.
[9]	HutterC，ZenklusenJC.TheCancerGenomeAtlas：Creating Lasting Value beyondIts Data[J].Cell，2018，173（2）：283-285.
[10]	Ding L，Bailey MH，Porta-Pardo E，et al.Perspective on Oncogenic Processes at theEnd ofthe Beginning of Cancer Genomics[J].Cell，2018，173（2）：305-320.
[11]	Wang Z，Jensen MA，Zenklusen JC.A Practical Guide to The Cancer Genome Atlas（TCGA）[J].Methods Mol Biol，2016，1418：111-141.
[12]	Sanchez-Vega F，Mina M，Armenia J，et al.Oncogenic Signaling Pathways in The Cancer Genome Atlas[J].Cell，2018，173（2）：321-337.
[13]	Malta TM，Sokolov A，Gentles AJ，et al.Machine Learning Identifies StemnessFeatures Associatedwith Oncogenic Dedifferentiation[J].Cell，2018，173（12）：338-354.
[14]	Yang R，Wang M，Zhang G，et al.E2F7-EZH2 axis regulates PTEN/AKT/mTOR signalling and glioblastoma progression[J].Br J Cancer，2020，123（9）：1445-1455.
[15]	Yao H，Lu F，Shao Y.The E2F family as potential biomarkers and therapeutic targets in colon cancer[J].Peer J，2020，8：e8562.
[17]	Dimova DK，Dyson NJ.The E2F transcriptional network：old acquaintances with new faces[J].Oncogene，2005，24（17）：2810-2826.
[16]	Sun CC，Zhou Q，Hu W，et al.Transcriptional E2F1/2/5/8 as potential targets and transcriptional E2F3/6/7 as new biomarkers for the prognosis of human lung carcinoma[J].Aging（Albany NY），2018，10（5）：973-987.